跳至主要内容
临床试验/JPRN-jRCTs071190055
JPRN-jRCTs071190055已完成未知

A single-center, open-label, single-arm, before and after comparison study to investigate the effects of Elobixibat administration in patients with heart failure complicated with chronic constipation

Tsujita Kenichi0 个研究点目标入组 50 人开始时间: 2020年3月27日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Patients with chronic constipation who meet every those following criteria
  • (At the time of registration(enrollment))
  • 1.Patients with chronic constipation who meet every those following criteria
  • 1) Meet 2 or more of the following six items
  • a. Straining during more than one-fourth (25%) of defections
  • b. Lumpy or hard stools (BSFS 1-2) more than one-fourth (25%) of defections
  • c. Sensation of incomplete evacuation more than one-fourth (25%) of defections
  • d. Sensation of anorectal obstruction/blockage more than one-fourth (25%) of defections
  • e. Manual maneuvers to facilitate more than one-fourth (25%) of defections (eg, digital evacuation, support of the pelvic floor)
  • f. Fewer than 3 spontaneous bowel movement per week
  • 2) Meet every those following 3 items
  • a. Rare to have loose stools without using laxtive
  • b. Never been given diagnosis as irriable bowel syndrome
  • c. Symptoms have been oresent since more than 6 months and meet the criteria 1.-1) for last 3 months..
  • 2.Outpatients with stable heart failure who meet every those following criteria
  • 1) Classification of NYHA cardiac function is belong to II or III.
  • 2) No change in any prescription for heart failure within 12 weeks before obtaining Informed Consent
  • 3) No hospitalization history for heart disease treatment within 6 months before obtaining Informed Consent
  • 4) Patients judged by doctors to be able to observe during the pre-observation and administration period
  • 3.Male and female over 20 years old at the date of Informed Consent
  • 4.Patients who are given sufficient description about participation in this study and sufficiently understand it, providing their consent in document by their own free will
  • 5.Patients who can write a defecation diary during the study period

排除标准

  • Patients who is applicable those followings to be excluded
  • (At the time of registration(enrollment), at theVisit 2)
  • 1.Patients with a history of hypersensitivity to Elobixibat
  • 2.Patients with confirmed or suspected bowel obstruction due to tumor, hernia, etc.
  • 3.Patients with severe hepatopathy (AST or ALT is 3 times or more for upper limit of in-hospital standard.)
  • 4.Patients to be suspected of having biliary atresia or a reducing secretion of bile acid
  • 5.Patients suspected of organic constipation
  • 6.Female patients who are pregnant, breastfeeding, or hope to raise children
  • 7.Patients who are taking bile acid preparations (ursodeoxycholic acid, chenodeoxycholic acid), aluminum-containing preparations (sucralfate hydrate, aldioxa, etc.), cholestyramine, colestimide or midazolam
  • 8.Patients who are judged to be ineligible for this research by investigator because of threatening the safety or poor protocol compliance
  • (At the Visit 2)
  • 9.Patients who have taken Elobixibat during the previous observation period

研究者

发起方
Tsujita Kenichi

相似试验